Do analysts prefer BCDA or GRDX?

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 2,747.38%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BCDA or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Entero Therapeutics N/A -49.81% -11.02%

Do analysts recommend ZYBT or BCDA?

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,747.38%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, ZYBT or BCDA?

BioCardia has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 2.43 -$9.98M N/A N/A BioCardia $60K 166.53 -$8.23M -$0.91 N/A

Is ZYBT or BCDA more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A BioCardia N/A -5,456.14% -232.75%

Does the media favor ZYBT or BCDA?

In the previous week, BioCardia had 13 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 15 mentions for BioCardia and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.34 beat BioCardia's score of 0.21 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BCDA or IXHL more profitable?

Incannex Healthcare's return on equity of -81.01% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Incannex Healthcare N/A -81.01% -76.11%

Does the media favor BCDA or IXHL?

In the previous week, BioCardia had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 15 mentions for BioCardia and 9 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.77 beat BioCardia's score of 0.21 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Incannex Healthcare 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCDA or RNXT more profitable?

BioCardia has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% RenovoRx -823.98% -135.03% -101.92%

Does the media prefer BCDA or RNXT?

In the previous week, BioCardia had 12 more articles in the media than RenovoRx. MarketBeat recorded 15 mentions for BioCardia and 3 mentions for RenovoRx. BioCardia's average media sentiment score of 0.21 beat RenovoRx's score of -0.47 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BCDA or ATOS more profitable?

Atossa Genetics' return on equity of -84.91% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Atossa Genetics N/A -84.91% -72.36%

Does the media favor BCDA or ATOS?

In the previous week, BioCardia had 12 more articles in the media than Atossa Genetics. MarketBeat recorded 15 mentions for BioCardia and 3 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.28 beat BioCardia's score of 0.21 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BioCardia (BCDA) Competitors

$0.88 +0.08 (+10.43%)

As of 01:23 PM Eastern

Compare

BCDA vs. GRDX, ZYBT, IXHL, RNXT, and ATOS

Should you buy BioCardia stock or one of its competitors? MarketBeat compares BioCardia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCardia include Entero Therapeutics (GRDX), Zhengye Biotechnology (ZYBT), Incannex Healthcare (IXHL), RenovoRx (RNXT), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry.

How does BioCardia compare to Entero Therapeutics?

BioCardia (NASDAQ:BCDA) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

BioCardia has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Entero Therapeutics has higher revenue and earnings than BioCardia. Entero Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	166.53	-$8.23M	-$0.91	N/A
Entero Therapeutics	$74.46K	491.61	-$6.39M	-$1.88	N/A

Entero Therapeutics' return on equity of -49.81% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Entero Therapeutics	N/A	-49.81%	-11.02%

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 2,747.38%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, BioCardia had 14 more articles in the media than Entero Therapeutics. MarketBeat recorded 15 mentions for BioCardia and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat BioCardia's score of 0.21 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Neutral
Entero Therapeutics	Very Positive

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BioCardia beats Entero Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BioCardia compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Zhengye Biotechnology's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
BioCardia	N/A	-5,456.14%	-232.75%

Zhengye Biotechnology has a beta of -2.4, meaning that its stock price is 340% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

20.6% of BioCardia shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioCardia has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.43	-$9.98M	N/A	N/A
BioCardia	$60K	166.53	-$8.23M	-$0.91	N/A

In the previous week, BioCardia had 13 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 15 mentions for BioCardia and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.34 beat BioCardia's score of 0.21 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,747.38%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioCardia beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does BioCardia compare to Incannex Healthcare?

BioCardia (NASDAQ:BCDA) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, BioCardia had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 15 mentions for BioCardia and 9 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.77 beat BioCardia's score of 0.21 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incannex Healthcare	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCardia has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market.

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 2,747.38%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 369.36%. Given BioCardia's higher probable upside, analysts clearly believe BioCardia is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare's return on equity of -81.01% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Incannex Healthcare	N/A	-81.01%	-76.11%

BioCardia has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	166.53	-$8.23M	-$0.91	N/A
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A

Summary

BioCardia beats Incannex Healthcare on 8 of the 12 factors compared between the two stocks.

How does BioCardia compare to RenovoRx?

BioCardia (NASDAQ:BCDA) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BioCardia had 12 more articles in the media than RenovoRx. MarketBeat recorded 15 mentions for BioCardia and 3 mentions for RenovoRx. BioCardia's average media sentiment score of 0.21 beat RenovoRx's score of -0.47 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia has higher earnings, but lower revenue than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	166.53	-$8.23M	-$0.91	N/A
RenovoRx	$1.49M	25.71	-$11.17M	-$0.33	N/A

BioCardia has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
RenovoRx	-823.98%	-135.03%	-101.92%

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 2,747.38%. RenovoRx has a consensus price target of $8.50, suggesting a potential upside of 901.18%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

BioCardia has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Summary

BioCardia beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does BioCardia compare to Atossa Genetics?

BioCardia (NASDAQ:BCDA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, BioCardia had 12 more articles in the media than Atossa Genetics. MarketBeat recorded 15 mentions for BioCardia and 3 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.28 beat BioCardia's score of 0.21 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCardia has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Atossa Genetics' return on equity of -84.91% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Atossa Genetics	N/A	-84.91%	-72.36%

BioCardia has higher revenue and earnings than Atossa Genetics. BioCardia is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	166.53	-$8.23M	-$0.91	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,747.38%. Atossa Genetics has a consensus target price of $24.50, suggesting a potential upside of 851.46%. Given BioCardia's higher possible upside, equities analysts clearly believe BioCardia is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioCardia beats Atossa Genetics on 7 of the 13 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.82M	$3.39B	$6.53B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.56%
P/E Ratio	-0.95	19.76	23.92	24.51
Price / Sales	166.53	315.37	537.13	123.07
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	10.98	8.32	10.68	6.84
Net Income	-$8.23M	$23.89M	$3.57B	$337.65M
7 Day Performance	-14.76%	1.77%	0.46%	2.52%
1 Month Performance	-21.61%	-0.26%	0.78%	3.57%
1 Year Performance	-60.09%	42.56%	23.23%	28.34%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.7145 of 5 stars	$0.88 +10.4%	$25.00 +2,747.4%	-64.7%	$9.82M	$60K	N/A	40	Analyst Forecast Analyst Revision Gap Down
GRDX Entero Therapeutics	1.0796 of 5 stars	$6.37 +2.4%	N/A	N/A	$41.38M	$40K	N/A	9	Positive News
ZYBT Zhengye Biotechnology	0.8314 of 5 stars	$0.89 +3.1%	N/A	-87.1%	$40.95M	$16.64M	N/A	278	Gap Down
IXHL Incannex Healthcare	1.9623 of 5 stars	$3.67 +7.9%	$18.00 +390.5%	-37.6%	$40.68M	$90K	N/A	3
RNXT RenovoRx	3.5977 of 5 stars	$0.86 -2.9%	$8.50 +888.4%	-36.4%	$39.94M	$1.12M	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. GRDX, ZYBT, IXHL, RNXT, and ATOS

How does BioCardia compare to Entero Therapeutics?

Summary

How does BioCardia compare to Zhengye Biotechnology?

Summary

How does BioCardia compare to Incannex Healthcare?

Summary

How does BioCardia compare to RenovoRx?

Summary

How does BioCardia compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. GRDX, ZYBT, IXHL, RNXT, and ATOS

How does BioCardia compare to Entero Therapeutics?

Which has more volatility and risk, BCDA or GRDX?

Which has higher earnings & valuation, BCDA or GRDX?

Is BCDA or GRDX more profitable?

Do analysts prefer BCDA or GRDX?

Does the media favor BCDA or GRDX?

Do institutionals & insiders hold more shares of BCDA or GRDX?

Summary

How does BioCardia compare to Zhengye Biotechnology?

Is ZYBT or BCDA more profitable?

Which has more risk & volatility, ZYBT or BCDA?

Do insiders & institutionals believe in ZYBT or BCDA?

Which has better earnings and valuation, ZYBT or BCDA?

Does the media favor ZYBT or BCDA?

Do analysts recommend ZYBT or BCDA?

Summary

How does BioCardia compare to Incannex Healthcare?

Does the media favor BCDA or IXHL?

Which has more volatility and risk, BCDA or IXHL?

Do institutionals and insiders have more ownership in BCDA or IXHL?

Do analysts rate BCDA or IXHL?

Is BCDA or IXHL more profitable?

Which has stronger earnings and valuation, BCDA or IXHL?

Summary

How does BioCardia compare to RenovoRx?

Do institutionals & insiders hold more shares of BCDA or RNXT?

Does the media prefer BCDA or RNXT?

Which has better valuation and earnings, BCDA or RNXT?

Is BCDA or RNXT more profitable?

Do analysts prefer BCDA or RNXT?

Which has more volatility and risk, BCDA or RNXT?

Summary

How does BioCardia compare to Atossa Genetics?

Does the media favor BCDA or ATOS?

Which has more risk & volatility, BCDA or ATOS?

Do institutionals and insiders hold more shares of BCDA or ATOS?

Is BCDA or ATOS more profitable?

Which has higher earnings & valuation, BCDA or ATOS?

Do analysts prefer BCDA or ATOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools